Menu

Visitors To Our Site
UNITED STATES
  40.9%
UNITED KINGDOM
  12.8%
RUSSIAN FEDERATION
  5.1%
ITALY
  4.2%
BOSNIA AND HERZEGOVINA
  3.3%
FRANCE
  3.2%
VIET NAM
  2.8%
NETHERLANDS
  2.7%
GERMANY
  2.6%
REPUBLIC OF KOREA
  2.4%
SWEDEN
  2.2%
SLOVENIA
  1.8%
CHINA
  1.7%
BELGIUM
  1.7%
PORTUGAL
  1.3%


Global Colon CancerAre you interested in joining our Global Colorectal Cancer Community? Please visit Global Colon Cancer.


You are here:  home > news 

News Articles

Please view the latest news articles from across Europe below. Alternatively, filter by news category or search by keyword.

Gene signature may improve colon cancer treatment



A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study by Vanderbilt-Ingram Cancer Center researchers.

The findings, published in the March issue of Gastroenterology, could help personalize treatments for colon cancer — the second leading cause of cancer-related deaths in the United States — by identifying patients most likely to benefit from chemotherapy.

In its early stages, colorectal cancer is treated with surgery only. However, between 20 percent and 25 percent of patients with Stage II disease (when the tumor has penetrated the muscular wall of the colon) will experience metastatic recurrence after surgical resection alone.

For stage III, when the cancer has spread to the lymph nodes, surgery is generally followed by chemotherapy — despite research showing that about 40 percent of stage III patients treated by surgery alone do not have a recurrence of disease in five years.

This suggests that identifying stage II patients at the greatest risk for recurrence — and targeting adjuvant chemotherapy to them — could decrease recurrences in that group. In addition, those stage III patients at lowest risk, if prospectively identified, could avoid having potentially toxic chemotherapy.

Using a mouse colon cancer cell line, R. Daniel Beauchamp, M.D., the John Clinton Foshee Distinguished Professor of Surgery and chair of the Section of Surgical Sciences, and colleagues identified 300 genes that showed distinct patterns of expression related to their ability to invade into a gel-like matrix, a test that reflects the aggressiveness of cancer cells.


For more details View the full story here

back

The information provided is for interest only and is not a substitute for professional medical advice. You should not rely on this information to make or refrain from making any decisions. Always obtain independent professional advice for your own particular health situation.
Registration No: 5314195 Registered Office: 92 Palatine Road, London N16 8ST.